corporate powerpoint template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050...

28
CIBENZA ® EP150 Practical application of Cibenza in feed. Some examples

Upload: others

Post on 05-Jul-2020

3 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

CIBENZA® EP150

Practical application of Cibenza in

feed. Some examples

Page 3: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

Mode of action

- Protein digestibility

- Gut flora modulation

Page 4: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

4

Poultry: digestibility study

procedures

• Ross 308 chicks

• Ad libitum access to feed

• Common diet from hatch to d 15 of age

• Test diets were fed from 16 to 21 d of age

• At day 21, chicks were euthanized to collect ileal contents

• Test ingredient is the only source of AA in diet

• When possible, diets were formulated to contain 20% CP

EP150

Page 5: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

5

CIBENZA DP 100 Standardized Ileal

Digestibility Determination Using

Accepted Methods/Diets

Page 6: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

6

CIBENZA DP 100 Standardized Ileal

Digestibility Determination Using

Accepted Methods/Diets

Page 7: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

7

CIBENZA DP 100 Standardized Ileal

Digestibility Determination Using

Accepted Methods/Diets

Arg His Ile Leu Lys Met M+C Phe Thr Trp Val EAA

SID

, %

0

45

50

55

60

65

70

75

80

85

90

95Control

DP100

*

**

*

*

* *

**

*

*P < 0.006

Corn EAA +4.5%p

Page 8: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

8

Gut microbiota modulation

Page 9: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

9

How can be reduced protein-microbiota interactions?

Better gut health

Less protein fermentation in caecum

Lower amino acids assimilated by bacteria.

Higher amount of amino acids and peptides absorbed by the host

Improve digestibility of crude protein from the diet

PROTEASES

Page 10: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

10

Bacterial 16S rRNA sequencing analysis:Species richness: total number of species within a habitat or community.Species evenness: relative contribution of each species to total number of individuals in a community.Species diversity: based on Shannon-Wiener Index (H), commonly used to characterize species diversity in a community:accounts for both richness and evenness of the species present..In

10000

20000

30000

40000

50000

60000

70000

PC NC NC+CibenzaEP150

Species richness

Internal Novus Research, B06IJE015018

P-value 0.0557

SEM 5.658

Cibenza EP150 modifies the intestinal

microbiota

a

a,b

b

PC NC NC+Cibenza EP150

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

PC NC NC+CibenzaEP150

Species eveness

P-value 0.0255

SEM 0.07

b

b

a

0

0.5

1

1.5

2

2.5

3

PC NC NC+CibenzaEP150

Species diversity

b

b

a

P-value 0.0190

SEM 0.295

total number of species

Gut microbiota

Page 11: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

11

b

a

bb

0

1

2

3

4

5

Normal CP High CP

Ileal Clostridium perfringens count in the digesta of 15 day-old broilers

Control Protease

Cibenza EP150 reduces the development of Clostridium perfringens

• 228 Ross broilers• floor pen, 2x2 factorial design• 9 replicate pens of 8 birds each, • 0-29 days of age, • all diets based on 20% rye and 25%

wheat (model subclinical enteritis)• coccidia challenge at day 7 : 3x vacc.dose

high protein diet with poultry by product meal.

Source of variation p-value

protein level 0.128

Cibenza EP150 0.107

protein x Cibenza EP150 0.043

Log cfu

Yan. et al, WPC 2012

Cibenza EP150

(22.12%) (30%)

Gut microbiota

Page 12: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

12

1,018 1,016984

798

600

650

700

750

800

850

900

950

1000

1050

Low CP High CP

Serum α-1-acid glycoprotein concentration day 22

Control Protease

Cibenza EP150 reduces inflammatory response

Yan et al., WPC 2012

Source of variation P-value

Protein level 0.72

Cibenza EP150 0.022

CP x Protease 0.74

Lower α-1-acid glycoprotein

Less gut imflamation

µg /ml

Cibenza EP150

Novus R&D 106IJD010011

(22.12%) (30%)

Gut microbiota

Page 13: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

13

CIBENZA EP150 TRIALS

1. Laying hens

2. Broilers

Page 14: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

14

Layers. Trial 1. Experimental Design

• Design

– Control vs. EP150 500 g/ton (6,792 birds)

• Treatments used

– Reduce 7.5% Crude Protein and Amino Acid

• Record

– Percentage of Egg production, Crack egg, White shell egg,

Feed intake, FCR, Egg mass

• Age: 45 week

• Date Start : October-November 2011 (8 week)

• Breed: H&N

Page 15: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

15

Layers. Trial 1.

Effect of Cibenza EP150 in Laying hen diets

80.0

82.0

84.0

86.0

88.0

90.0

45 46 47 48 49 50 51 52

CIBENZA DP100

CONTROL

EGG PRODUCTION

65.00

65.10

65.20

65.30

65.40

65.50

65.60

CIBENZADP100

CONTROL

65.51 65.48

48.50

48.70

48.90

49.10

49.30

49.50

CIBENZA DP100 CONTROL

49.13

48.99

AVERAGE EGG WEIGHT EGG PER HEN

HOUSE

EP150 EP150

Page 16: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

16

Layers. Trial 2

replaced 10% CP

5,000 hen layer pen trial, week 32 to 52

3 treatments : control, low protein (-10%), low protein plus EP150

Anderson et al, 2007

3632

96

94

92

90

40

a

b

a

ab

aa

ba

ab

a

98

4844 52

-10% CP -10% CP + EP150 Control

weeks

Eg

g p

rod

ucti

on

%

Trial sta

rts

Page 17: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

17

One of the 3 largest egg producers in RU (3.5 Mio Layers, 900 Mio

eggs/y)

Objective

feed cost reduction program with Cibenza EP150

Protocol

Start: week 35; 52 000 birds in control and treatment groups

2,5% matrix use for two weeks, 5% matrix next two weeks and 7,5% matrix for 8 weeks

Results:

Feed cost reduction: app. 7,6 €/mt

Cost of feed consumption per 1000 eggs (€): 32,73 vs31,68 (-1 €)

Amount of sellable eggs: 86,3% vs 87,9% (+1,6%)

Dirty eggs: 6,7%vs 5,4% (-1,3%)

Broken+ soft eggs: 2,5% vs 2,2% (-0,3%)

Egg shell strength, Newton: 37,4 vs 36,8 (-0,6)

Findings: the economy from feed cost reduction (only!!) during the year will be €1,1 MIO

Layers Trial 3. Borovskaya

Page 18: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

18

4.5

6.7

2.5

4.5

5.4

2.2

1.5

2

2.5

3

3.5

4

4.5

5

5.5

6

6.5

7

Incision Dirty eggs Broken+softshell

Control Cibenza DP100

86.3

87.9

85.5

86

86.5

87

87.5

88

88.5

Sellable eggs,%

Control Cibenza DP100

Borovskaya trial

Egg quality parameters

+1.6%

Difference in non-conform eggs between

non supplemented and Cibenza EP150

fed birds%

Increase in saleable egg yield (%)

with Cibenza EP150

EP150EP150

Page 19: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

19

Control Cibenza EP150Reduction

with EP150

Feed cost,€/t 256.4 249.3 -7.11

Feed consumption per 1000

eggs, kg127,7 127,1 -0,6

Feed consumption cost per

1000 eggs, €32,73 31,68 -1,04

Feed consumption /

total egg production

per year, mt

127 700 127 100 -600

Total annual feed

costs (based on the

overall farm egg gross

output), €

32 742 280 31 686 030 -1 056 250

Borovskaya trial

ROI effect from feed cost

reduction

Page 20: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

20

3 treatments x 8 pens x 45 broilers

Control, Negative Control -7.5% CP & AA, Negative Control with

EP150 0.5 kg/ton

-7.5% CP

-7.5% CP + EP150

Control

ab

a

1

1.2

1.4

1.6

1.8

2

2.2

2.4

2.6

35d 42d

Live weight (kg)

P<0.05

b

ab

a

a

c

b

1

1.1

1.2

1.3

1.4

1.5

1.6

1.7

1.8

1.9

35d 42d

Feed conversion ratio

P<0.05

P= 0.065

Atlanta, GA , 2011

Broilers. Trial 1

EP150 replaced 7.5% CP & AA

Page 21: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

21

b

ab

aa a

a

2.25

2.27

2.29

2.31

2.33

2.35

2.37

2.39

2.41

2.43

2.45

Low Medium High

(Kg)

AA levels

BWG

Control

Cibenza

a

ab

bcbc

bc

c

1.80

1.85

1.90

1.95

Low Medium High

AA levels

Feed:Intake ratio

Control

Cibenza

*Dig Lys Low = 1,09; 0,98; 0,84; 0,79

Med = 1,15; 1,03; 0,88; 0,83

High = 1,21; 1,08; 0,93; 0,87

Corn/soy pelleted diets

Wang et al., 2006 JAPR

Broilers. Trial 2

EP150 replaced 10% CP & AA

Capacity of EP150 to compensate

performance losses when reducing

up to 10% CP

Page 22: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

22

Objective field trial:

• To assess the value of CIBENZA EP150 as a nutritional tool to lower dietary costs while maintaining an optimal bird performance, in comparison to a standard feed without a protease.

• CIBENZA® EP150 is a unique feed additive containing an intrinsically heat stable protease which improves animal performance and has a favorable effect on dietary protein.

• CIBENZA EP150 usage can reduce ration costs by lowering the level of costly protein sources in the feed or optimizing the use of lower digestible, cheaper alternative sources, without sacrificing animal performance.

Broilers. Trial 3

In field trial

Page 23: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

23

Performance results

Parameter Control CIBENZA EP150Improvement with

CIBENZA EP150

FCR 1,649 1,645 -0.4pts

No. of placement pullets 104 900 105 300

Mortality (%) 3,547 4,004*

Average slaughter age (d) 41,9 41,9

Avg LW (kg) 2,863 2,928 +2.27%

EBI (pts) 399,84 407,93 +2%

Avg. Cost/t feed € 299,05 296,93

* higher mortality in House 3 in the last week of growth, related to cardio-respiratory problems (not linked to the treatment)

• Nr of antibiotic treatments was the same in both groups• Litter quality and cleanliness of feathers were experienced to be better for the CIBENZA EP150 fed birds

2.12€/tnet

savings

Page 24: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

24

CIBENZA EP150 FEED EXAMPLES

Page 25: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

25

Broiler, starter feed21CP, 2900Kcal, 1,20ALys

Page 26: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

26

Broiler, starter feed21CP, 2900Kcal, 1,20ALys

Page 27: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

27

• Contributes to secure gut health

– Less undigested protein for proteolityc fermentation (Clostri/E.coli)

• Allow to reduce feed cost

– Reformulate with matrix evaluating impact on each ingredient

• Effect per ingredient evaluated based on animal trials

• Saving on “ME” + “CP” + “dig aa”

Practical indications for application

Incorporation 250 g / ton feed

Page 28: Corporate PowerPoint Template · 12. 1,018 1,016 984 798 600 650 700 750 800 850 900 950 1000 1050 Low CP High CP Serum α-1-acid glycoprotein concentration day 22 Control Protease

28

Thank you for your time.

Questions?

Products not available in all countries.

NOTICE: While the information contained herein (“Information”) is presented in good faith and believed to be correct as of the date hereof, Novus International, Inc., does not

guarantee satisfactory results from reliance upon such Information, disclaims all liability for any loss or damage arising out of any use of this Information or the products to which

said Information refers and MAKES NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS OR IMPLIED, OF MERCHANTABILITY, FITNESS FOR A PARTICULAR

PURPOSE OR OF ANY OTHER NATURE WITH RESPECT TO THE INFORMATION OR PRODUCTS, except as set forth in Novus’s standard conditions of sale. Nothing

contained herein is to be construed as a recommendation to use any product or process in conflict with any patent, and Novus International, Inc., makes no representation or

warranty, express or implied, that the use thereof will not infringe any patent.

®NOVUS and CIBENZA are trademarks of Novus International, Inc., and are registered in the United States and other countries.

TM SOLUTIONS SERVICE SUSTAINABILITY and NOVABASE are trademarks of Novus International, Inc.

© 2014 Novus International, Inc. All rights reserved.